Objective: To observe the clinical efficacy of Tongbu Xinbao capsule on chronic heart failure (Qi deficiency blood stasis and water flux type)

in order to investigate the mechanism of Tongbu Xinbao capsule on chronic heart failure. Method: A total of 120 patients with chronic heart failure outpatients or inpatient patients were randomly divided into treatment group and control group

with 60 cases in each group. The control group got western medicine for basic treatment; in addition to the therapy of the control group

the treatment group was also given Tongbu Xinbao capsule

4 capsule

tid

for 4 weeks. After the treatment

the clinical efficacy of the two groups were observed; and before and after treatment

symptom score

N-terminal-proBNP (NT-proBNP)

plasma renin aetivity (PRA)

aldosterone (ALD)

angiotensin Ⅱ (AngⅡ) and homocysteic acid (HCY) levels were observed

and the blood

urine

stool routine

liver and kidney function and other laboratory parameters were detected to determine the toxic and side effects of Tongbu Xinbao capsule. Result: Efficacy of traditional Chinese medicine(TCM) syndrome of treatment group was 91.67%

which was significantly higher than 81.67% of control group. After treatment

PRA

AngⅡ

ALD

HCY

NT-proBNP were significantly decreased than before treatment

and those in the treatment group were superior to those of the control group (P<0.05). Conclusion: Conventional western medicine combined with Tongbu Xinbao capsule showed a significant therapeutic effect

suggesting that the combined administration can better inhibit RASS activity and reduced HCYof patients with heart failure

which may be related to the inhibition of PRA

Ang11

ALD

HCY

with no toxic or side effect and a reliable efficacy.